BiotechTube

Febuxostat + Tigulixostat

Phase 3Recruiting
0 views this week 0 watching⚡ Active
Interest: 47/100
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Gout

Conditions

Gout

Trial Timeline

Mar 25, 2026 → Oct 30, 2027

NCT ID
NCT07414394

About Febuxostat + Tigulixostat

Febuxostat + Tigulixostat is a phase 3 stage product being developed by Innovent Biologics for Gout. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07414394. Target conditions include Gout.

What happened to similar drugs?

12 of 20 similar drugs in Gout were approved

Approved (12) Terminated (3) Active (7)
✅LumiracoxibNovartisApproved
✅Pegloticase + MethotrexateAmgenApproved
✅Pegloticase + Methotrexate (MTX)AmgenApproved
✅Pegloticase + Methotrexate (MTX) + Standard Gout Flare Prophylaxis + Infusion Reaction (IR) ProphylaxisAmgenApproved
✅Pegloticase + methotrexate + placebo + gout flare prophylaxis regimen + fexofenadine + acetaminophen + methylprednisoloneAmgenApproved
✅Etanercept + Triamcinolone AcetonideAmgenApproved
✅PegloticaseAmgenApproved

Hype Score Breakdown

Clinical
17
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT07414394Phase 3Recruiting

Competing Products

20 competing products in Gout

See all competitors
ProductCompanyStageHype Score
febuxostat + AllopurinolAstellas PharmaPhase 3
40
Dotinurad + FebuxostatEisaiPhase 3
40
BaricitinibEli LillyPhase 2
35
HR091506 tablets + placebo of febuxostat tablets + febuxostat tablets + placebo of HR091506 tabletsJiangsu Hengrui MedicinePhase 1
25
SHR4640 tablet + SHR4640 tablet + febuxostat tablet + SHR4640 placebo tabletJiangsu Hengrui MedicinePhase 2
31
repaglinide; midazolam; SHR4640 + repaglinide; midazolam; SHR4640; SHR4640 placebo + repaglinide; midazolam; SHR4640 placeboJiangsu Hengrui MedicinePhase 1
29
SHR4640 + placeboJiangsu Hengrui MedicinePhase 1
29
SHR4640 dose1 + SHR4640 dose2 + Placebo oral tablet + Allopurinol 300 MGJiangsu Hengrui MedicinePhase 3
40
Colchicine + Febuxostat + SHR4640Jiangsu Hengrui MedicinePhase 1
29
SHR4640 + AllopurinolJiangsu Hengrui MedicinePhase 3
40
SHR4640 ；Febuxostat + SHR4640 ; Febuxostat + SHR4640 + SHR4640 + FebuxostatJiangsu Hengrui MedicinePhase 2
42
SHR4640Jiangsu Hengrui MedicinePhase 1
25
HR091506 tablets + placebo of febuxostat tablets + febuxostat tablets + placebo of HR091506 tabletsJiangsu Hengrui MedicinePhase 3
47
HR091506 tablets + placebo of febuxostat tablets + febuxostat tablets + placebo of HR091506 tabletsJiangsu Hengrui MedicinePhase 3
40
SHR4640 + PlaceboJiangsu Hengrui MedicinePhase 1
29
Zurampic® + Control group: xanthine oxidase inhibitor monotherapyAstraZenecaPre-clinical
18
Risk of selected safety eventsAstraZenecaPre-clinical
26
AZD6140 + Placebo to match AZD6140AstraZenecaPhase 1
29
RDEA3170 + Allopurinol + PlaceboAstraZenecaPhase 2
35
RDEA3170 + Febuxostat + BenzbromaroneAstraZenecaPhase 1/2
32